RikOssenkoppele

The Alzheimer's disease 2024 drug development pipeline

An often heard critique is that the Alzheimer field is too “amyloid-centric”. The Figure below actually shows a well-diversified drug pipeline, which is highly needed.

The mechanisms of action (CADRO) for agents currently being tested in phase 2 clinical trials (n=90) are:

1. Inflammation (23%)
2. Neurotransmitter receptors (19%)
3. Amyloid (12%)
4. Synaptic plasticity (12%)
5. Tau (7%)
6. Other [eg, Metabolism, Oxidative stress, Lipids] (27%)

Link to Cummings et al. > alz-journals.onlinelibrary.wiley.com/doi/10.1002/tr…

#Alzheimers #Dementia #EndAlz #drugs #trials

🚨NEW PREPRINT: An atypical phenotype is a risk factor for higher mortality in Alzheimer’s disease

@ilse_bader shows that an atypical (non-amnestic-predominant) clinical presentation is an important risk factor for mortality beyond age, sex, education, APOEε4-carriership and disease severity.

Link @medrxivpreprint: medrxiv.org/content/10.110…

@Colin__Groot @AlzheimerAms

Survey among experts on the future role of tau-PET in clinical practice and trials

Check out our latest work led by @vermeiren_marie & @IsmaelLCalandri, describing the results of a survey among 268 dementia experts on the future role of Tau PET in the clinic and trials.

Many thanks to all respondents!!!

Link (open access) > alz-journals.onlinelibrary.wiley.com/doi/10.1002/da…

@AlzheimerAms

FYI.

IWG 2024 vs AA 2024 criteria for Alzheimer disease

A comparison between the recently proposed Alzheimer Association criteria vs the updated IWG criteria for AD. Differences are in the Table below: mainly comprising differing views on AD as a "biological" vs "clinical-biological" entity and therefore most pronounced in cognitively unimpaired individuals.

Link to paper > jamanetwork.com/journals/jaman…